

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 6/19/1952  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Prostate-Specific Kallikrein, 4Kscore**

ARUP test code 2014059

4K - Biopsy History

NO BIOPSY

Performed by: BioReference Laboratories, Inc.  
481 Edward H. Ross Dr  
Elmwood Park, NJ 07407

James Weisberger, M.D.,

4K - Digital Rectal Exam (DRE)

NO NODULE

Performed by: BioReference Laboratories, Inc.  
481 Edward H. Ross Dr  
Elmwood Park, NJ 07407

James Weisberger, M.D.,

4K - Score

6 %

**H=High, L=Low, \*=Abnormal, C=Critical**

Evaluation: **LOW RISK**  
For a patient aged 60 years or older with a Total PSA  $\geq$  3 ng/mL and a 4Kscore  $<$ 7.5%, the probability of not developing distant metastases within the next 10 years is 99.8%. This test was developed and its performance characteristics were determined by BioReference Laboratories. It has not been cleared by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform this test.  
NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.  
NOTE: Biotin supplementation ( $>$ 5 mg/day) may cause interference with assays that are components of the 4Kscore Test, and may impact the 4Kscore result.  
Digital Rectal Exam (DRE): **NO NODULE**  
Prior Biopsy Status: **NO PRIOR BIOPSY**  
Performed by: BioReference Laboratories, Inc.  
481 Edward H. Ross Dr  
Elmwood Park, NJ 07407

James Weisberger, M.D.,

**4K - PSA, Total**

1.70 ng/mL (Ref Interval:  $<$ 4.00)

NOTE: NCCN Guidelines(1.2017) recommend repeat testing every 2-4 years if PSA is  $<$ 1 ng/mL and every 1-2 years if PSA is 1-3 ng/mL in men aged 45 to 75 years. A PSA value of 1.00 ng/mL selects for the upper range of PSA values. Men who have a PSA above the median for their age group are at a higher risk for prostate cancer and for the aggressive form of the disease. The higher above the median, the greater the risk.  
NOTE: The PSA assay should not be the only test used for diagnostic purposes. Additional evaluation using DRE, ultrasound, TUR or similar procedures may be used for this purpose. Predictions of disease recurrence should not be based solely upon values obtained from serial PSA values obtained on the patient.  
NOTE: Values obtained with different assay methods or kits cannot be used interchangeably.  
NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.  
ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics)  
NOTE: Biotin supplementation ( $>$ 5mg/day) may cause interference with this assay.  
Performed by: BioReference Laboratories, Inc.  
481 Edward H. Ross Dr  
Elmwood Park, NJ 07407

James Weisberger, M.D.,

**H=High, L=Low, \*=Abnormal, C=Critical**

4K - PSA, Free

0.36 ng/mL (Ref Interval: Not Estab.)

NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Values obtained with different assay methods or kits cannot be used interchangeably.

ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics).

NOTE: Biotin supplementation (>5mg/day) may cause interference with this assay.

Performed by: BioReference Laboratories, Inc.  
481 Edward H. Ross Dr  
Elmwood Park, NJ 07407

James Weisberger, M.D.,

4K - PSA, Percent Free

21 % (Ref Interval: See Below)

FREE PSA RISK ASSESSMENT

The probability of prostate cancer for men with non-suspicious DRE results, by age group, using PSA values between 4.000 and 10.000 ng/mL and percent FREE PSA

values is summarized in the table below:

PROBABILITY OF CANCER\*

%free PSA	(50-59 yrs)	(60-69 yrs)	(>or=70 yrs)
<or=10	49.2%	57.5%	64.5%
11-18	26.9%	33.9%	40.8%
19-25	18.3%	23.9%	29.7%
>25	9.1%	12.2%	15.8%

\*probability of finding prostate cancer by needle biopsy

NOTE: Calculation of percent FREE PSA may not be possible when the value for

TOTAL PSA is in the low normal range. These guidelines are for assays

performed using the Roche E602 immunoassay system.(8/2015;v8.0)

Performed by: BioReference Laboratories, Inc.  
481 Edward H. Ross Dr  
Elmwood Park, NJ 07407

James Weisberger, M.D.,

H=High, L=Low, \*=Abnormal, C=Critical

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
4K - Biopsy History	20-220-133558	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
4K - Digital Rectal Exam (DRE)	20-220-133558	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
4K - Score	20-220-133558	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
4K - PSA, Total	20-220-133558	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
4K - PSA, Free	20-220-133558	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
4K - PSA, Percent Free	20-220-133558	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 20-220-133558  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 4 of 4 | Printed: 2/23/2021 1:43:43 PM  
4848